220 Asymptomatic First Degree Relatives of Crohn's Patients Display Endoscopic Small Intestinal Lesions Independent of Their Gut Permeability Status
Christopher Teshima(University of Alberta), Levinus A. Dieleman(University of North Carolina at Chapel Hill), Marilyn Gordon(University of Calgary), Ronda G. Danchak(University of Alberta), Karen Madsen(University of Alberta), Jon Meddings, Daniel L. Wong, Peter Ho(Epizyme (United States)), Hien Q. Huynh(University of Alberta), Amanda Mullins(University of Alberta), Mohamed El‐Kalla(University of Alberta), Samina A. Turk(University of Alberta)
Cited by 2
Related Papers
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Intestinal barrier function in health and gastrointestinal disease
|Neurogastroenterology & Motility|2012|886
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
|The Lancet Oncology|2018|614
Increased Intestinal Permeability Is Associated With Later Development of Crohn’s Disease
|Gastroenterology|2020|308
Reduction of Colitis by Prebiotics in HLA-B27 Transgenic Rats Is Associated with Microflora Changes and Immunomodulation
|Inflammatory Bowel Diseases|2005|215